Abstract
Biological toxins are highly diverse and produced in nature by a wide variety of organisms. A number of key features favor the potential threat of these biotoxins as bioterror agents, including their high potency, the relatively long latency period before symptoms are manifested, the difficulty in detecting or diagnosing their presence and identity, and their relative ease in production and stability in the environment. All of these features also create major challenges in developing tools and reagents to combat toxin-mediated diseases. So far, there have been a limited number of toxins that have drawn attention for potential use as bioterror agents, but there are many more naturally occurring toxins that have been isolated, purified, and characterized, as well as cloned and modified to make different recombinant variants. Current treatments for toxin exposure are limited to vaccination or passive immunization with antibodies; however, there are no postexposure therapies available after symptoms have manifested. A vigilant and robust biotoxin research community must be mobilized to not only better characterize the existing biotoxins but also to anticipate new variants or entirely new biotoxins that might arise and to develop appropriate antitoxin countermeasures. In addition, a definitive roadmap must also be formulated for safe, documented, and controlled handling of biotoxins during basic research and during development of toxin-based therapeutics for biomedical applications.
References
Abramson SN, Radic Z, Manker D, Faulkner DJ, Taylor P. Onchidal: a naturally occurring irreversible inhibitor of acetylcholinesterase with a novel mechanism of action. Mol Pharmacol. 1989;36(3):349–54.
Aktories K, editor. Botulinum neurotoxins. Heidelberg: Springer; 2013.
Alouf JE, Popoff MR, editors. The comprehensive sourcebook of bacterial protein toxins. 3rd ed. San Diego: Elsevier/Academic; 2006.
Anderson PD. Bioterrorism: toxins as weapons. J Pharm Pract. 2012;25(2):121–9.
Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285(8):1059–70.
Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med. 2006;354(5):462–71.
Barash JR, Arnon SS. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis. 2014;209(2):183-91.
Bennett JW, Klich M. Mycotoxins. Clin Microbiol Rev. 2003;16(3):497–516.
Bigalke H, Rummel A. Medical aspects of toxin weapons. Toxicology. 2005;214(3):210–20.
Binder P, Attre O, Boutin JP, Cavallo JD, Debord T, Jouan A, et al. Medical management of biological warfare and bioterrorism: place of the immunoprevention and the immunotherapy. Comp Immunol Microbiol Infect Dis. 2003;26(5–6):401–21.
Blunden G. Biologically active compounds from marine organisms. Phytother Res. 2001;15(2):89–94.
Calvete JJ, Sanz L, Angulo Y, Lomonte B, Gutierrez JM. Venoms, venomics, antivenomics. FEBS Lett. 2009;583(11):1736–43.
CDC. National Center for Emerging and Zoonotic Infectious Disease: national botulism surveillance summaries – 2001–2011. [Summary Report] 2011 [updated 06/25/2013; cited 08/08/2013]; http://www.cdc.gov/nationalsurveillance/botulism_surveillance.html (2011).
Crenshaw M. Explaining terrorism: causes, processes and consequences (political violence). 1st ed. Wilkinson P, Rapoport D, editors. New York: Routledge/Taylor & Francis Group; 2011.
Daly JW, Spande TF, Garraffo HM. Alkaloids from amphibian skin: a tabulation of over eight-hundred compounds. J Nat Prod. 2005;68(10):1556–75.
De Castro C, Holst O, Lanzetta R, Parrilli M, Molinaro A. Bacterial lipopolysaccharides in plant and mammalian innate immunity. Protein Pept Lett. 2012;19(10):1040–4.
Dittmann E, Fewer DP, Neilan BA. Cyanobacterial toxins: biosynthetic routes and evolutionary roots. FEMS Microbiol Rev. 2013;37(1):23–43.
Dover N, Barash JR, Hill KK, Xie G, Arnon SS. Molecular characterization of a novel botulinum neurotoxin type H gene. J Infect Dis. 2014;209(2):192-202.
Edupuganti OP, Ovsepian SV, Wang J, Zurawski TH, Schmidt JJ, Smith L, et al. Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin. FEBS J. 2012;279(14):2555–67.
Escoubas P. Molecular diversification in spider venoms: a web of combinatorial peptide libraries. Mol Divers. 2006;10(4):545–54.
Ganesan K, Raza SK, Vijayaraghavan R. Chemical warfare agents. J Pharm Bioallied Sci. 2010;2(3):166–78.
Hallen HE, Luo H, Scott-Craig JS, Walton JD. Gene family encoding the major toxins of lethal Amanita mushrooms. Proc Natl Acad Sci U S A. 2007;104(48):19097–101.
Henghold 2nd WB. Other biologic toxin bioweapons: ricin, staphylococcal enterotoxin B, and trichothecene mycotoxins. Dermatol Clin. 2004;22(3):257–62, v.
Hill SE, Iqbal R, Cadiz CL, Le J. Foodborne botulism treated with heptavalent botulism antitoxin. Ann Pharmacother. 2013;47(2):e12.
Ho M, Chang LH, Pires-Alves M, Thyagarajan B, Bloom JE, Gu Z, et al. Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting. Protein Eng Des Sel. 2011;24(3):247–53.
Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T. Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep. 2008;25(3):447–54.
Hu WG, Yin J, Chau D, Negrych LM, Cherwonogrodzky JW. Humanization and characterization of an anti-ricin neutralization monoclonal antibody. PLoS One. 2012;7(9):e45595.
Hwang DF, Noguchi T. Tetrodotoxin poisoning. Adv Food Nutr Res. 2007;52:141–236.
Joseph R, Pahari S, Hodgson WC, Kini RM. Hypotensive agents from snake venoms. Curr Drug Targets Cardiovasc Haematol Disord. 2004;4(4):437–59.
Katona P. Botulinum toxin: therapeutic agent to cosmetic enhancement to lethal biothreat. Anaerobe. 2012;18(2):240–3.
Kim IJ, Blanke SR. Remodeling the host environment: modulation of the gastric epithelium by the Helicobacter pylori vacuolating toxin (VacA). Front Cell Infect Microbiol. 2012;2:37.
Mackessy SP, editor. Handbook of venoms and toxins of reptiles. Boca Raton: Taylor & Francis Group/CRC Press; 2010.
Madsen JM. Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents. Clin Lab Med. 2001;21(3):593–605.
Makarovsky I, Markel G, Hoffman A, Schein O, Brosh-Nissimov T, Tashma Z, et al. Strychnine–a killer from the past. Isr Med Assoc J. 2008;10(2):142–5.
McCleary RJ, Kini RM. Snake bites and hemostasis/thrombosis. Thromb Res. 2013;132:642–6.
Morens DM, Fauci AS. Emerging infectious diseases: threats to human health and global stability. PLoS Pathog. 2013;9(7):e1003467.
Olivera BM, Teichert RW. Diversity of the neurotoxic Conus peptides: a model for concerted pharmacological discovery. Mol Interv. 2007;7(5):251–60.
Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med. 2007;58:221–37.
Paterson RR. Fungi and fungal toxins as weapons. Mycol Res. 2006;110(Pt 9):1003–10.
Popoff MR. Botulinum neurotoxins: more and more diverse and fascinating toxic proteins. J Infect Dis. 2014;209(2):168-9.
Relman DA. Inconvenient truths in the pursuit of scientific knowledge and public health. J Infect Dis. 2014;209(2):170-2.
Salem H. Issues in chemical and biological terrorism. Int J Toxicol. 2003;22(6):465–71.
Satchell KJ. Structure and function of MARTX toxins and other large repetitive RTX proteins. Annu Rev Microbiol. 2011;65:71–90.
Schep LJ, Temple WA, Butt GA, Beasley MD. Ricin as a weapon of mass terror–separating fact from fiction. Environ Int. 2009;35(8):1267–71.
Shimada K, Ohishi K, Fukunaga H, Ro JS, Nambara T. Structure-activity relationship of bufotoxins and related compounds for the inhibition of Na+, K+-adenosine triphosphatase. J Pharmacobiodyn. 1985;8(12):1054–9.
Sudhof TC. alpha-Latrotoxin and its receptors: neurexins and CIRL/latrophilins. Annu Rev Neurosci. 2001;24:933–62.
Szinicz L. History of chemical and biological warfare agents. Toxicology. 2005;214(3):167–81.
US Code of Law. Title: 18: Crimes and criminal procedure (Part I – Crimes). Chapter 10: Biological weapons. Sect. 178: Definitions (2012).
Wilson BA. Global biosecurity in a complex, dynamic world. Complexity. 2008;14(1):71–88.
Wilson BA, Ho M. Recent insights into Pasteurella multocida toxin and other G-protein-modulating bacterial toxins. Future Microbiol. 2010;5(8):1185–201.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media Dordrecht
About this entry
Cite this entry
Wilson, B.A., Ho, M. (2014). Biosecurity and Toxins. In: Gopalakrishnakone, P. (eds) Toxinology. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6645-7_18-1
Download citation
DOI: https://doi.org/10.1007/978-94-007-6645-7_18-1
Received:
Accepted:
Published:
Publisher Name: Springer, Dordrecht
Online ISBN: 978-94-007-6645-7
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences